on BioNxt Solutions Inc. (isin : CA0909741062)
BioNxt Solutions Expands Patent Portfolio for Drug Delivery Innovations
BioNxt Solutions Inc., a leader in bioscience, has expanded its intellectual property portfolio with new international patents. These patents focus on sublingual delivery technologies for autoimmune neurodegenerative diseases. This development follows a positive International Preliminary Report on Patentability from the European Patent Office in September 2024.
The company has initiated patent filings in the United States, Canada, Europe, and Japan. These patents aim to protect BioNxt's proprietary sublingual formulations for anticancer drugs, repurposed for conditions like Multiple Sclerosis (MS). BioNxt's leading product, BNT23001, demonstrates promising absorption rates and plans for clinical trials in 2025.
The company has outlined key objectives for 2025, including launching clinical trials, preparing regulatory submissions, and fostering partnerships. BioNxt is also exploring pipeline expansion and industry engagement to advance its sublingual drug delivery platform.
R. H.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all BioNxt Solutions Inc. news